TITLE

Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine

AUTHOR(S)
Kaskas, B.A.; Louis, E.; Hindorf, U.; Schaeffeler, E.; Deflandre, J.; Graepler, F.; Schmiegelow, K.; Gregor, M.; Zanger, U.M.; Eichelbaum, M.; Schwab, M.
PUB. DATE
January 2003
SOURCE
Gut;Jan2003, Vol. 52 Issue 1, p140
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the finding that Crohn's disease patients with thiopurine S-methyltransferase (TPMT) deficiency can be successfully treated with azathioprine (AZA). Cases where treatment has been successful and toxicity has been avoided by titrating the drug dose; View that very low TPMT activity demands pharmacogenetically guided dosing.
ACCESSION #
9758423

 

Related Articles

  • A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Dotan, Iris; Rachmilewitz, Daniel; Schreiber, Stefan; Eliakim, Rami; Van der Woude, C. Janneke; Kornbluth, Asher; Buchman, Alan L.; Bar-Meir, Shimon; Bokemeyer, Bernd; Goldin, Eran; Maaser, Christian; Mahadevan, Uma; Seidler, Ursula; Hoffman, Jörg C.; Homoky, Douglas; Plasse, Terry; Powers, Barbara; Rutgeerts, Paul; Hommes, Daniel // Gut;Jun2010, Vol. 59 Issue 6, p11 

    The article presents a study on the optimal dose of intravenous semapimod HCl for patients with moderate to severe Crohn's disease. The randomized, double-blind, placebo-controlled trial involved the use of multicentre outpatient clinics. Results revealed the ineffectiveness of single and 3-day...

  • SULFASALAZINE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2008, p770 

    The article presents information on sulfasalazine, a drug used for the treatment of ulceration and bleeding from ulcerative colitis and Crohn's disease. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are...

  • Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs? Vande Casteele, Niels; Gils, Ann // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2571 

    No abstract available.

  • Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Steenholdt, Casper; Brynskov, Jørn; Thomsen, Ole; Munck, Lars; Fallingborg, Jan; Christensen, Lisbet; Pedersen, Gitte; Kjeldsen, Jens; Jacobsen, Bent; Oxholm, Anne; Kjellberg, Jakob; Bendtzen, Klaus; Ainsworth, Mark // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2762 

    Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim: This study investigated long-term economic...

  • Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States Loftus, Edward V.; Pan, Xiaoyun; Zurawski, Pete; Mulani, Parvez; Chao, Jingdong // Journal of Crohn's & Colitis;Dec2011, Vol. 5 Issue 6, p550 

    Abstract: Background and aims: To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn''s disease (CD). Methods: Patients with CD receiving adalimumab maintenance therapy (≥3 dispensing events within 1year) were identified from a large specialty...

  • Infliximab.  // Reactions Weekly;11/28/2009, Issue 1280, p28 

    The article describes the case of a 32-year-old man who developed delayed hypersensitivity reaction after receiving mercaptopurine and infliximab infusion for fistulous Crohn's disease. Symptoms experienced by the patient include fever, jaw pain, myalgia, chest tightness and dyspnoea. Infliximab...

  • Metronidazole.  // Reactions Weekly;2/14/2004, Issue 988, p11 

    Presents the case of a 74-year-old woman who developed encephalopathy and inferior olivary hypertrophy while receiving metronidazole for Crohn's disease. Dosage and duration of the treatment; Symptoms revealed by a cranial nerve examination; Response of the patient to cyanocobalamin therapy.

  • Takayasu's arteritis progression on anti-TNF biologics: a case series. Osman, Mohammed; Aaron, Stephen; Noga, Michelle; Yacyshyn, Elaine // Clinical Rheumatology;May2011, Vol. 30 Issue 5, p703 

    Takayasu's arteritis (TA) is a rare granulomatous vasculitic disease that affects the aorta and its major branches. Recent studies have suggested that anti-TNFα biological therapies are highly effective in treating TA refractory to conventional immunosuppressive therapy. We describe two...

  • ADRENOCORTICOIDS (Systemic).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, p16 

    The article presents information on adrenocorticoids (systemic), a drug used for treatment of different medical problems like allergic diseases, blood disorders, kidney diseases, asthma, Crohn's disease and some cancers. The dosage and usage information is provided. The possible adverse...

  • OLSALAZINE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, p624 

    The article presents information on olsalazine, an inflammatory bowel disease suppressant used for the treatment of ulcerative colitis and Crohn's disease. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics